Showing results (491-500 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|September 25, 2018
Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1Juan P Jaworski, Pedro Cahn
The Lancet. HIV|September 25, 2018
Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage studyNancy A Hessol, Hannah Whittemore, Eric Vittinghoff, et al.
The Lancet. HIV|September 28, 2018
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial
The Lancet. HIV|July 6, 2019
Management of active tuberculosis in adults with HIVGraeme Meintjes, James C M Brust, James Nuttall, et al.
The Lancet. HIV|April 17, 2023
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort studyDenton Callander, Hamish McManus, Richard T Gray, et al.
The Lancet. HIV|April 23, 2021
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort studyCasey L Smiley, Peter F Rebeiro, Carina Cesar, et al.
The Lancet. HIV|May 6, 2023
Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants: a systematic review of modelling studiesStanzi M le Roux, Jasantha Odayar, Catherine G Sutcliffe, et al.
The Lancet. HIV|August 9, 2020
Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort studyMichael E Herce, Christopher J Hoffmann, Katherine Fielding, et al.
The Lancet. HIV|August 9, 2020
Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science frameworkJillian Pintye, Dvora L Joseph Davey, Anjuli D Wagner, et al.
The Lancet. HIV|May 25, 2023
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trialRulan Griesel, Ying Zhao, Bryony Simmons, et al.
Pageof 79